Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Inclusion Criteria: * Age ≥ 18 years, male or female. * Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification * Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment. * Tumor tissue genotyping performed and results available prior to enrollment. * ECOG 0, 1, or 2. * Life expectancy greater than 3 months. * Adequate organ function * Contraception during study * Informed consented Exclusion Criteria: * Has a prior malignancy other than the malignancies under study within 3 years without relieve * Primary CNS lymphoma * Known hypersensitivity to any study drug. * Pregnant or lactation * Active infection. * Diseases and medical history: 1. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers 2. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 3. Has a history of psychoactive substance abuse that cannot be discontinued 4. Has any severe and/or uncontrolled disease. * Uncontrollable autoimmune disease, * Not able to comply to the protocol for mental or other unknown reasons * Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.